Enhancing in vitro cytotoxicity of doxorubicin against MCF-7 breast cancer cells in the presence of water-soluble β-cyclodextrin polymer as a nanocarrier agent
This study was aimed to evaluate the impact of water-soluble β–cyclodextrin polymer (β-CDP), as a nanocarrier, on the therapeutic efficacy of the commercial doxorubicin (DOX). The β-CDP was synthesized by cross-linking of β-CD using epichlorohydrin. The chemical structure of the cross-linked β-CDP was verified by NMR and thermogravimetric analysis.
The solubility of β-CDP in water was around 880 g in 1000 mL. Next, the DOX/β-CDP was formulated by the addition of the polymer into the various concentrations of DOX in a weight ratio of 1:10 and 1:20 (DOX: β-CDP). The formation of the inclusion complex of DOX with β-CDP was studied by UV–Vis spectroscopy. The UV–Vis spectra of DOX/β-CDP formulations show the appearance of the absorption peak at 480 nm and a significant decrease in the absorbance intensity of DOX signal compared to DOX solution. This verified the formation of the DOX/β-CDP complex and also the presence of free DOX in the DOX/β-CDP formulation. The hydrodynamic size of DOX/β-CDP formulation was obtained in the range of nanometer, and the complexion of DOX by β-CDP leads to a negative shift in the zeta potential. In vitro release profile shows a burst release followed by sustained release of DOX from DOX/β-CDP formulation.
This is due to the presence of both free and encapsulated DOX. The cytotoxic effect of DOX solution and DOX/β-CDP formulation was evaluated by MTT assay against breast cancer (MCF-7) cell line. The anticancer activity of the DOX/β-CDP was higher than the DOX.
Article information: Gholam-Hosseinpour, M., Karami, Z., Hamedi, S. et al. Enhancing in vitro cytotoxicity of doxorubicin against MCF-7 breast cancer cells in the presence of water-soluble β-cyclodextrin polymer as a nanocarrier agent. Polym. Bull. (2021). https://doi.org/10.1007/s00289-021-03569-1